Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX)

CAPS Rating: 2 out of 5

A biopharmaceutical company focusing on the development and commercialization of innovative therapeutic products to treat the unmet medical needs of patients with debilitating conditions and life-threatening diseases.

Recs

0
Player Avatar nhanhsong (< 20) Submitted: 6/23/2010 6:09:13 AM : Underperform Start Price: $5.62 PGNX Score: -29.87

If PGNX can't find a new partner for RELISTOR this year, it will face some difficulty with finance.

Featured Broker Partners


Advertisement